Enliven insider plans sale of 45,000 shares

Enliven Therapeutics filed a notice of proposed insider sales under Rule 144.

Rhea-AI Filing Summary

Enliven Therapeutics filed a notice of proposed insider sales under Rule 144. The filing covers up to 45,000 shares of common stock, with an aggregate market value of $1,202,400.00, to be sold through Jefferies LLC on or about February 17, 2026 on the NASDAQ exchange.

The 45,000 shares were acquired on August 9, 2022 via stock options from Enliven Therapeutics Inc. The filing also notes that 59,000,000 shares of common stock were outstanding. The seller represents they are not aware of undisclosed material adverse information about the company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Enliven Therapeutics (ELVN) Form 144 filing disclose?

The Form 144 discloses a planned sale of up to 45,000 Enliven Therapeutics common shares. These shares are intended to be sold under Rule 144, indicating a proposed disposition of restricted or control securities by an affiliate or other covered holder.

How many Enliven Therapeutics (ELVN) shares are planned for sale and at what value?

The filing covers a proposed sale of 45,000 common shares with an indicated aggregate market value of $1,202,400.00. This value reflects the market price used in the form and frames the potential transaction size for investors reviewing the notice.

When are the Enliven Therapeutics (ELVN) shares expected to be sold under this Form 144?

The Form 144 lists an approximate sale date of February 17, 2026. This is the target timeframe for executing sales, subject to market conditions, Rule 144 requirements, and any actual trading decisions made by the selling party.

How were the Enliven Therapeutics (ELVN) shares in this Form 144 originally acquired?

The 45,000 Enliven Therapeutics common shares were acquired on August 9, 2022 through stock options. The issuer listed is Enliven Therapeutics Inc., and the form notes the acquisition method directly in the securities acquisition table.

Which broker and exchange are involved in the planned Enliven Therapeutics (ELVN) share sale?

The proposed sale is to be executed through Jefferies LLC, located at 520 Madison Avenue, New York. The shares are expected to trade on the NASDAQ exchange, as specified in the Form 144 securities information section.

How many Enliven Therapeutics (ELVN) shares were outstanding according to this Form 144?

The Form 144 notes that 59,000,000 Enliven Therapeutics common shares were outstanding. This provides a baseline context for the size of the proposed 45,000-share sale relative to the company’s total common equity base.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:40 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001701247
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Collins Helen Louise
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	45000	1202400.00	59000000	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/09/2022	Stock Options	Enliven Therapeutics Inc.			45000	08/09/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 10/19/2025, and all representations regarding material non-public information were made as of the adoption of the plan.
Date of Notice	02/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	10/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Helen Collins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)